PUBLISHER: Lucintel | PRODUCT CODE: 1386129
PUBLISHER: Lucintel | PRODUCT CODE: 1386129
The future of the global respiratory virus vaccine market looks promising with opportunities in the physician office, hospital, clinic, and pharmacy/store markets. The global respiratory virus vaccine market is expected to reach an estimated $13.5 billion by 2030 with a CAGR of 7.4% from 2024 to 2030. The major drivers for this market are rising rate of respiratory viral infections, growing awareness of vaccine benefits, and increasing government spending to fast track the development of vaccines and ensure widespread access.
A more than 150-page report is developed to help in your business decisions.
The study includes a forecast for the global respiratory virus vaccine by type, route of administration, indication, end use, and region.
Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies respiratory virus vaccine companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the respiratory virus vaccine companies profiled in this report include-
Lucintel forecasts that inactivated/killed is expected to witness highest growth over the forecast period due to its ability to stimulate a powerful and enduring immune response.
Within this market, hospital is expected to witness highest growth over the forecast period.
North America is expected to witness highest growth over the forecast period due to strong healthcare infrastructure and government funding.
Market Size Estimates: Respiratory virus vaccine market size estimation in terms of value ($B).
Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.
Segmentation Analysis: Respiratory virus vaccine market size by various segments, such as by type, route of administration, indication, end use, and region in terms of ($B).
Regional Analysis: Respiratory virus vaccine market breakdown by North America, Europe, Asia Pacific, and Rest of the World.
Growth Opportunities: Analysis of growth opportunities in different types, route of administrations, indications, end uses, and regions for the respiratory virus vaccine market.
Strategic Analysis: This includes M&A, new product development, and competitive landscape of the respiratory virus vaccine market.
Analysis of competitive intensity of the industry based on Porter's Five Forces model.
FAQ
Answer: The global respiratory virus vaccine market is expected to reach an estimated $13.5 billion by 2030.
Answer: The global respiratory virus vaccine market is expected to grow with a CAGR of 7.4% from 2024 to 2030.
Answer: The major drivers for this market are rising rate of respiratory viral infections, growing awareness of vaccine benefits, and increasing government spending to fast track the development of vaccines and ensure widespread access.
Answer: The future of the respiratory virus vaccine market looks promising with opportunities in the physician office, hospital, clinic, and pharmacy/store markets.
Answer: Some of the key respiratory virus vaccine companies are as follows:
Answer: Lucintel forecasts that inactivated/killed is expected to witness highest growth over the forecast period due to its ability to stimulate a powerful and enduring immune response.
Answer: North America is expected to witness highest growth over the forecast period due to strong healthcare infrastructure and government funding.
Answer: Yes, Lucintel provides 10% customization without any additional cost.